Summary & Overview

HCPCS Level II J7604: Acetylcysteine Inhalation Solution, Compounded Product

HCPCS Level II code J7604 designates acetylcysteine inhalation solution as a compounded unit-dose product billed per gram for administration through durable medical equipment. This code matters nationally because it captures billing for compounded nebulized mucolytic therapy used in respiratory care where commercially available preparations may not meet patient-specific dosing or formulation needs. Accurate coding affects payment, clinical documentation, and access to appropriate inhalation therapy in outpatient and home settings.

Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for inhalation acetylcysteine, the service setting implications for DME-based administration, and which payers commonly process claims for this service. The publication outlines typical billing considerations, common modifiers that may be applied during claim submission, and how this HCPCS Level II code relates to compounded medication workflows.

This summary provides national-level context useful for coding teams, billing professionals, and policy analysts seeking benchmarks, documentation expectations, and payer-facing coding guidance. Data not available in the input: specific payer pricing, utilization benchmarks, associated taxonomies, and ICD-10 pairings.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareJ7604HCPCS Level IIacetylcysteineinhalation therapycompounded medicationdurable medical equipmentnebulizerunit doserespiratory care

Billing Code Overview

HCPCS Level II code J7604 represents acetylcysteine, inhalation solution, compounded product, supplied in unit dose form and billed per gram. The service involves a compounded inhalation medication intended for administration via durable medical equipment (DME) designed for aerosol delivery.

Service Type: Inhalation therapy — compounded nebulized solution

Typical Site of Service: Home or outpatient setting with DME (nebulizer or aerosol delivery device)

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult or pediatric individual with thickened airway secretions due to cystic fibrosis, bronchiectasis, or acute mucus plugging from inhalational injury who requires inhaled mucolytic therapy. The patient is prescribed compounded inhalation-grade acetylcysteine in unit-dose form to be administered via a durable medical equipment nebulizer at home or in an outpatient clinic. The clinical workflow begins with the prescribing clinician (pulmonologist, pediatric pulmonologist, or respiratory therapist) verifying indication and dose per gram units, ordering the compounded J7604 product from a pharmacy compounding service, and coordinating DME delivery of the nebulizer and supplies. A respiratory therapist provides training on nebulizer use, storage, and dose administration, documents tolerance and effectiveness, and communicates any adverse reactions to the prescriber. Follow-up visits assess sputum clearance, pulmonary function tests, and need for ongoing therapy.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	Use when complexity or time for patient education or administration is substantially greater than typical for inhalation therapy.
`23`	Unusual anesthesia	Not routinely used for inhalation; limited to rare cases with unexpected anesthesia for administration.
`52`	Reduced services	Use when planned inhalation therapy was partially provided or dose reduced.
`53`	Discontinued procedure	Use if therapy initiated but discontinued due to adverse reaction prior to intended administration.
`54`	Surgical care only	Rarely applicable; not typical for this DME-administered inhalation product.
`55`	Postoperative management only	Not commonly used for inhalation therapy billing.
`56`	Preoperative management only	Not commonly used.
`62`	Two surgeons	Not applicable to medication administration; generally not used.
`AS`	Ambulatory surgical center	Use to indicate service performed in an ASC setting when applicable.
`CO`	Workers' compensation	Use for services covered by workers' compensation payor.
`CQ`	Service furnished under Medicare demonstration project	Use when applicable to demonstration projects.
`QX`	CRNA service with medical direction by physician (modifier for anesthesia)	Use only when CRNA services meet criteria; rarely applicable.
`QY`	Medical direction of two CRNAs by one physician	Rarely applicable for this therapy.
`TG`	Via oral or nasal tracheal tube	Use when inhalation solution is administered through a tracheostomy or endotracheal tube.

Taxonomy Code	Specialty	Notes
`207RP0000X`	Pulmonary Disease	Pulmonologists prescribe and oversee inhaled mucolytic therapy.
`2086S0102X`	Pediatric Pulmonology	Pediatric specialists manage cystic fibrosis and bronchiectasis therapy in children.
`235Z00000X`	Respiratory Therapy	Respiratory therapists provide administration training and device management.
`3336C0002X`	Clinical Pharmacy	Compounding pharmacists prepare unit-dose inhalation acetylcysteine.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E84.0`	Cystic fibrosis with pulmonary manifestations	Primary indication for inhaled mucolytic therapy to reduce sputum viscosity and improve clearance.
`J47.9`	Bronchiectasis, unspecified	Chronic bronchial dilation with excessive mucus production treated with mucolytics.
`J44.9`	Chronic obstructive pulmonary disease, unspecified	COPD patients with mucus hypersecretion may receive inhaled mucolytics in select cases.
`T59.1X1A`	Toxic effect of smoke, accidental initial encounter	Inhalational injury with mucous plugging where inhaled acetylcysteine may be used to loosen secretions.
`R09.3`	Abnormal sputum	Symptom code supporting therapeutic use of mucolytics for excessive or abnormal sputum production.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`94640`	Pressurized or non-pressurized inhalation treatment for acute airway obstruction or for sputum induction for diagnostic purposes (e.g., with an aerosol generator)	Used for supervised inhalation treatments in clinic when administering inhaled medications like nebulized acetylcysteine.
`94644`	Inhalation treatment for acute airway obstruction; with nebulizer, administration of bronchodilator(s) including spirometry or peak flow measurement	May accompany mucolytic therapy if bronchodilator administration or monitoring is required.
`94664`	Demonstration and/or evaluation of patient utilization of an aerosol generator, nebulizer, metered dose inhaler or IPPB device	Respiratory therapist education and demonstration when issuing a DME nebulizer for `J7604` administration.
`94010`	Breathing capacity test; spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with reporting of multiple parameters	Pulmonary function testing performed during follow-up to assess response to mucolytic therapy.
`99070`	Supplies and materials (eg, drugs, disposables) provided by the physician over and above those usually included with the office visit	Occasionally used for billing additional supplies related to administration when payor policy allows.